Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech , a leading veterinary diagnostics company.
- HENDERSON, Nev., April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now available in-clinic to veterinarians across the U.S and Europe through Antech , a leading veterinary diagnostics company.
- By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer¹ earlier and help pet owners make timely, informed decisions about cancer care."
- Volition's original license and supply agreement was between Belgian Volition SRL and Heska, an Antech company, part of Mars Science & Diagnostics.
- https://doi.org/10.1186/s12917-022-03429-8
According to The Veterinary Cancer Society, one in four dogs will be diagnosed with cancer, and it's the leading cause of death in pets who are beyond middle age.